Virtus ETF Advisers’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Virtus ETF Advisers’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,612	Closed	-$365K	–	499
2020 Q1	$365K	Sell	7,612 -1,123	-13%	-$52.2K	0.15%	203
2019 Q4	$410K	Sell	8,735 -3,146	-26%	-$139K	0.07%	246
2019 Q3	$281K	Sell	11,881 -662	-5%	-$19.6K	0.06%	203
2019 Q2	$377K	Sell	12,543 -3,645	-23%	-$83.5K	0.08%	193
2019 Q1	$363K	Sell	16,188 -1,662	-9%	-$35.7K	0.77%	44
2018 Q4	$325K	Buy	+17,850	New	+$280K	0.06%	93

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Virtus ETF Advisers's RARX Position: Q2 2020 in Review

Virtus ETF Advisers sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 7,612 shares — an estimated $365K sold.

Virtus ETF Advisers first reported a position in RARX in Q4 2018 and held it in 6 quarters. The position peaked at $410K in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Virtus ETF Advisers reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Virtus ETF Advisers sold 7,612 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $365K.
Virtus ETF Advisers first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
Virtus ETF Advisers's Ra Pharmaceuticals, Inc. Common Stock position peaked at $410K in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.